key: cord-0690887-hbfqa3vk
authors: Murillo-Zamora, Efrén; Mendoza-Cano, Oliver; Delgado-Enciso, Iván; Hernandez-Suarez, Carlos M.
title: Predictors of severe symptomatic laboratory-confirmed SARS-COV-2 reinfection
date: 2021-02-12
journal: Public Health
DOI: 10.1016/j.puhe.2021.01.021
sha: 089e9b3a95c0dcc9734dfadfc504b52b2ff3e26b
doc_id: 690887
cord_uid: hbfqa3vk

Objective To evaluate factors predicting severe symptomatic laboratory-confirmed (reverse transcription-quantitative polymerase chain reaction, RT-qPCR) SARS-COV-2 (severe acute coronavirus-2) reinfection. Study design A nationwide retrospective cohort study was conducted in Mexico. Method Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RR) and 95% confidence intervals (CI) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-COV-2 infection. Results The risk of severe disease was 14.7% and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, p < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-COV-2 reinfection were increasing age (RR per year = 1.007, 95% CI 1.003-1.010), comorbidities (namely obesity [RR = 1.12, 95% CI 1.01-1.24], asthma [RR = 1.26, 95% CI 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI 1.07 - 1.38] and previous severe laboratory-confirmed COVID-19 (RR = 1.20, 95% CI 1.03-1.39). Conclusions To the best of our knowledge this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-COV-2 reinfection and factors associated with illness severity was characterized. Our results may contribute to the current knowledge of SARS-COV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.

The COVID-19 (coronavirus disease 2019) caused by SARS-COV-2 (severe acute 31 respiratory coronavirus 2) pandemic has had a major impact in healthcare systems. In 32 Mexico, by middle January 2021, more than 1.6 million confirmed cases and nearly 142 33 thousand deaths had been registered [1] . 34 Even when there is not a consensus regarding its definition, reinfection risk is a major 35 debate related to the COVID-19 pandemic [2] . Given the high observed mortality in 36 Mexico, there is concern regarding the impact of subsequent COVID-19 in recovered 37 patients. The aim of this study was to evaluate factors predicting severe SARS-COV-2 38 symptomatic reinfection in a large cohort of laboratory-confirmed COVID-19 survivors.

We conducted a nationwide retrospective cohort study including adults (aged 20 years or our study became asymptomatic between both episodes. 90 We would like to highlight that enrolled patients who recovered to severe primary illness 91 had a 20% increase in the risk of severe subsequent disease (RR = 1.20, 95% CI 1.03-1.39). ii. We analyzed disease outcomes in a large subset (n = 258) of laboratoryconfirmed (reverse-transcription quantitative polymerase chain reaction) cases of symptomatic SARS-COV-2 reinfection.

iii.

To the best of our knowledge this is the first study evaluating illness outcomes in a large number of laboratory-positive patients and our results may be highly relevant for public health policymakers.

COVID-19 in Mexico: General data

Setting the criteria for SARS-145

CoV-2 reinfection -six possible cases

Male gender and 147 kidney illness are associated with an increased risk of severe laboratory-confirmed 148 coronavirus disease

Virological assessment of hospitalized patients with COVID-151 2019

153 Antibody responses to SARS-CoV-2 in patients with COVID-19

COVID-19 Risk Factors Among Health 156 Workers: A Rapid Review

Threat Assessment Brief: 158 Reinfection with SARS-CoV-2: considerations for public health response

Predictors of symptomatic laboratory-confirmed SARS-COV-2 164 reinfection

Government of Mexico and Health Ministery. Clinical guidelines for the attention of 168 COVID-19 patients